Innoviva EBITDA 2012-2026 | INVA
Innoviva ebitda from 2012 to 2026. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
|
Innoviva Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $206 |
| 2024 | $209 |
| 2023 | $152 |
| 2022 | $495 |
| 2021 | $398 |
| 2020 | $343 |
| 2019 | $265 |
| 2018 | $259 |
| 2017 | $202 |
| 2016 | $126 |
| 2015 | $49 |
| 2014 | $-18 |
| 2013 | $-21 |
| 2012 | $-18 |
| 2011 | $-102 |
|
Innoviva Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2026-06-30 | $61 |
| 2026-03-31 | $49 |
| 2025-12-31 | $49 |
| 2025-09-30 | $45 |
| 2025-06-30 | $59 |
| 2025-03-31 | $52 |
| 2024-12-31 | $54 |
| 2024-09-30 | $54 |
| 2024-06-30 | $65 |
| 2024-03-31 | $36 |
| 2023-12-31 | $48 |
| 2023-09-30 | $28 |
| 2023-06-30 | $37 |
| 2023-03-31 | $38 |
| 2022-12-31 | $30 |
| 2022-09-30 | $297 |
| 2022-06-30 | $87 |
| 2022-03-31 | $82 |
| 2021-12-31 | $110 |
| 2021-09-30 | $100 |
| 2021-06-30 | $102 |
| 2021-03-31 | $85 |
| 2020-12-31 | $90 |
| 2020-09-30 | $90 |
| 2020-06-30 | $81 |
| 2020-03-31 | $81 |
| 2019-12-31 | $79 |
| 2019-09-30 | $65 |
| 2019-06-30 | $64 |
| 2019-03-31 | $57 |
| 2018-12-31 | $82 |
| 2018-09-30 | $63 |
| 2018-06-30 | $68 |
| 2018-03-31 | $46 |
| 2017-12-31 | $72 |
| 2017-09-30 | $45 |
| 2017-06-30 | $52 |
| 2017-03-31 | $33 |
| 2016-12-31 | $42 |
| 2016-09-30 | $32 |
| 2016-06-30 | $30 |
| 2016-03-31 | $22 |
| 2015-12-31 | $21 |
| 2015-09-30 | $13 |
| 2015-06-30 | $10 |
| 2015-03-31 | $5 |
| 2014-12-31 | $5 |
| 2014-09-30 | $-5 |
| 2014-06-30 | $-6 |
| 2014-03-31 | $-11 |
| 2013-12-31 | $22 |
| 2013-09-30 | $-6 |
| 2013-06-30 | $-5 |
| 2013-03-31 | $-31 |
| 2012-12-31 | $-28 |
| 2012-09-30 | $-31 |
| 2012-06-30 | $-34 |
| 2012-03-31 | $88 |
| 2011-12-31 | $-33 |
| 2011-09-30 | $-27 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.510B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1071.528B | 36.15 |
| Johnson & Johnson (JNJ) | United States | $641.804B | 24.52 |
| AbbVie (ABBV) | United States | $462.493B | 24.08 |
| Merck (MRK) | United States | $357.370B | 45.12 |
| Roche Holding AG (RHHBY) | Switzerland | $349.105B | 0.00 |
| Novartis AG (NVS) | Switzerland | $265.214B | 16.01 |
| Novo Nordisk (NVO) | Denmark | $194.004B | 10.81 |
| Pfizer (PFE) | United States | $157.995B | 9.09 |
| Sanofi (SNY) | France | $105.050B | 8.84 |
| Bayer (BAYRY) | Germany | $56.081B | 9.98 |